Check Before You Invest : Concord Drugs Ltd

Snapshot

Q.1 Which industry/sub-sector does Concord Drugs Ltd belong to?

Concord Drugs Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Concord Drugs Ltd a good quality company?

Concord Drugs Ltd is a average quality company, based on a somewhat consistent 10-year financial track record.

Q.3 Is Concord Drugs Ltd undervalued or overvalued?

Concord Drugs Ltd appears Overvalued, as its key valuation ratios are above with their past averages.

Q.4 Is Concord Drugs Ltd a good buy now?

Concord Drugs Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Concord Drugs Ltd?

Concord Drugs Ltd revenue growth is -14.6% for FY-2025, which is below its 5-year CAGR of -6.38%, indicating slower growth.

Q.2 Return on capital employed (ROCE) of Concord Drugs Ltd?

Concord Drugs Ltd Return on capital employed is 4.73% for FY-2025, which is below its 5-year historical median of 5.97%. The current ROCE is below its estimated weighted average cost of capital (WACC) of 14%, indicating value preservation.

Q.3 Return on Asset of Concord Drugs Ltd?

Concord Drugs Ltd Return on Asset is 0.51%, which is below its 5-year historical median of 1.58%, indicating deteriorated asset utilization efficiency.

Q.4 Return on Equity (ROE) of Concord Drugs Ltd?

Concord Drugs Ltd Return on equity is 0.87% for FY-2025, which is below its 5-year historical median of 3%, indicating the business is making worse use of its shareholders capital.

Q.5 Cash conversion cycle of Concord Drugs Ltd?

Concord Drugs Ltd Cash conversion cycle is 283 days, above its 5-year historical median of 217 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover	0.64	0.91
ROE	0.87	3
ROCE	4.73	5.97
Cash Conversion Cycle	283 days	217 days

Q.6 Gross Profit margin of Concord Drugs Ltd?

Concord Drugs Ltd Gross profit margin which is the profit after deduction of direct costs, is 5.6% for FY-2025, which is above its 5-year median of 5.3%, indicating increasing margins.

Q.7 Operating Profit Margin of Concord Drugs Ltd?

Concord Drugs Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 10.19% for FY-2025, which is above its 5-year median of 8.5% indicating increasing margins.

Q.8 Net Profit Margin of Concord Drugs Ltd?

Concord Drugs Ltd Net Profit Margin is 0.8% for FY-2025, is below with its 5-year median of 1.74%, indicating decreasing margins.

	Current Level	5-year Historic Median
Gross Profit Margin	5.6	5.3
Operating Profit Margin	10.19	8.5
Net Profit Margin	0.8	1.74

Q.9 Debt to Equity ratio of Concord Drugs Ltd?

Concord Drugs Ltd Debt-to-Equity ratio is 0.50, which is above with the industry average of 0.27, indicating higher debt levels in the industry.

Q.10 Debt to cash flow from operations of Concord Drugs Ltd?

Concord Drugs Ltd Debt to cash flow from operations is 5.35, which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Concord Drugs Ltd?

Promoters hold 54.39% of the Concord Drugs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Concord Drugs Ltd vs industry peers?

Concord Drugs Ltd revenue CAGR is -6.38%, compared to the industry median CAGR of 8.30%, indicating slower growth and losing its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth	-14.6	8.3
Gross Profit Growth	-	14.7
Operating Profit Growth	-	11.4
Net Profit Growth	0	NAN

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover	0.64	0.81
ROE	0.87	9.49
ROCE	4.73	11.91
Cash Conversion Cycle (days)	282.64	85

Valuation & price assessment

Q.1 Stock return of Concord Drugs Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 4.3% based on the current price.

Q.2 What return has the stock given over the last decade?

	9Y	5Y	3Y	1Y
Share Price CAGR	4.3%	21.9%	41.6%	184.2%

Q.3 Valuation ratios of Concord Drugs Ltd vs historical?

The current P/E is higher that its historical median.

Q.4 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	212.42	28.57	31.09
Price to Book	2.43	1.01	2.85
Price to Sales	2.32	0.69	2.79
EV to EBITDA	33.63	11.39	15.87

Check more companies

6. Wockhardt

7. Pfizer

8. Piramal Pharma

9. Acutaas Chemicals

10. Astrazeneca Pharma I

Check trending companies

1. Force Motors Ltd.

2. KEI Industries Ltd.

3. Aadhar Housing Finance Ltd.

4. State Bank Of India

5. Power Finance Corporation Ltd.